Cognition Therapeutics plans late-stage zervimesine trial for Lewy body dementia psychosis

Cognition Therapeutics, Inc.

Cognition Therapeutics, Inc.

CGTX

0.00
  • Cognition Therapeutics met the FDA on May 20, 2026 to review Phase 2 results for zervimesine (CT1812) in dementia with Lewy bodies patients with psychosis, outlining a proposed registrational study.
  • The discussion was described as positive, supporting a path forward to move the drug into a late-stage program for this indication.
  • Formal FDA meeting minutes are expected in June, setting up the next decision point for the registrational trial design and endpoints.
  • The company also noted zervimesine is being studied in the Phase 2 START trial in mild cognitive impairment and early Alzheimer’s disease.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cognition Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605210730PRIMZONEFULLFEED9724360) on May 21, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.